 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of 4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underw 